Publicaciones en las que colabora con Rosario Calvo Duo (45)

2013

  1. A predictive pharmacokinetic/pharmacodynamic model of fentanyl for analgesia/sedation in neonates based on a semi-physiologic approach

    Pediatric Drugs, Vol. 15, Núm. 3, pp. 247-257

  2. Tacrolimus dose individualization in "de novo" patients after 10 years of experience in liver transplantation: Pharmacokinetic considerations and patient pathophysiology

    International Journal of Clinical Pharmacology and Therapeutics, Vol. 51, Núm. 7, pp. 606-614

  3. Tacrolimus pharmacokinetics in the early post-liver transplantation period and clinical applicability via Bayesian prediction

    European Journal of Clinical Pharmacology, Vol. 69, Núm. 1, pp. 65-74

2011

  1. Pathophysiological idiosyncrasies and pharmacokinetic realities may interfere with tacrolimus dose titration in liver transplantation

    European Journal of Clinical Pharmacology, Vol. 67, Núm. 7, pp. 671-679

2010

  1. Simulation of sirolimus exposures and population variability immediately post renal transplantation: Importance of the patient's CYP3A5 genotype in tailoring treatment

    Biopharmaceutics and Drug Disposition, Vol. 31, Núm. 2-3, pp. 129-137

2007

  1. Modeling methadone pharmacokinetics in rats in presence of P-glycoprotein inhibitor valspodar

    Pharmaceutical Research, Vol. 24, Núm. 7, pp. 1299-1308

2006

  1. The role of unbound drug in pharmacokinetics/pharmacodynamics and in therapy

    Current Pharmaceutical Design, Vol. 12, Núm. 8, pp. 977-987

2005

  1. Altered dose-to-effect of propofol due to pharmacokinetics in rats with experimental diabetes mellitus

    Journal of Pharmacy and Pharmacology, Vol. 57, Núm. 3, pp. 317-325

  2. Bicompartmental kinetics of tobramycin analysed with a wide range of covariates

    International Journal of Antimicrobial Agents, Vol. 26, Núm. 4, pp. 304-311

  3. Pharmacokinetic-pharmacodynamic modeling of the hydroxy lerisetron metabolite L6-OH in rats: An integrated parent-metabolite model

    Pharmaceutical Research, Vol. 22, Núm. 11, pp. 1769-1782

  4. Time-dependent pharmacokinetics of cyclosporine (Neoral®) in de novo renal transplant patients

    Journal of Clinical Pharmacy and Therapeutics, Vol. 30, Núm. 6, pp. 549-557

2004

  1. Alpha-1-acid glycoprotein directly affects the pharmacokinetics and the analgesic effect of methadone in the rat beyond protein binding

    Journal of Pharmaceutical Sciences, Vol. 93, Núm. 11, pp. 2836-2850

  2. Effect of P-glycoprotein inhibition on methadone analgesia and brain distribution in the rat

    Journal of Pharmacy and Pharmacology, Vol. 56, Núm. 3, pp. 367-374

  3. Influence of formulation on propofol pharmacokinetics and pharmacodynamics in anesthetized patients

    Acta Anaesthesiologica Scandinavica, Vol. 48, Núm. 8, pp. 1038-1048

2003

  1. Age-related changes in pharmacokinetics and pharmacodynamics of lerisetron in the rat: A population pharmacokinetic model

    Gerontology, Vol. 49, Núm. 4, pp. 205-214

2002

  1. 'In vitro' binding of propofol to serum lipoproteins in thyroid dysfunction

    European Journal of Clinical Pharmacology, Vol. 58, Núm. 9, pp. 615-619

  2. Effect of omeprazole on oral and intravenous RS-methadone pharmacokinetics and pharmacodynamics in the rat

    Journal of Pharmaceutical Sciences, Vol. 91, Núm. 7, pp. 1627-1638

  3. Pharmacokinetics and pharmacological effect of lerisetron, a new 5-HT3 antagonist, in rats

    Journal of Pharmaceutical Sciences, Vol. 91, Núm. 1, pp. 41-52

  4. Pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase efavirenz [2]

    British Journal of Clinical Pharmacology

  5. Prediction of unbound propofol concentrations in a diabetic population

    Therapeutic Drug Monitoring, Vol. 24, Núm. 6, pp. 689-695